Literature DB >> 32280167

Integration of denosumab therapy in the management of giant cell tumors of bone.

Daniel T Miles1, Ryan T Voskuil2, Wood Dale3, Joel L Mayerson2, Thomas J Scharschmidt2.   

Abstract

A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
© 2020 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Denosumab; Giant cell tumor of the bone (GCTB); RANKL

Year:  2020        PMID： 32280167      PMCID： PMC7136643          DOI： 10.1016/j.jor.2020.03.020

Source DB:  PubMed          Journal:  J Orthop        ISSN： 0972-978X


  98 in total

1.  Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis.

Authors:  Linda Moskovszky; Károly Szuhai; Tibor Krenács; Pancras C W Hogendoorn; Miklós Szendroi; Maria Serena Benassi; László Kopper; Tibor Füle; Zoltán Sápi
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

2.  Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up.

Authors:  K A Siebenrock; K K Unni; M G Rock
Journal:  J Bone Joint Surg Br       Date:  1998-01

3.  Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?

Authors:  Andrea Sambri; Manuel R Medellin; Costantino Errani; Laura Campanacci; Tomohiro Fujiwara; Davide Donati; Michael Parry; Robert Grimer
Journal:  J Orthop Sci       Date:  2019-05-30       Impact factor: 1.601

4.  Response evaluation of giant-cell tumor of bone treated by denosumab: Histogram and texture analysis of CT images.

Authors:  Jisook Yi; Young Han Lee; Sang Kyum Kim; Seung Hyun Kim; Ho-Taek Song; Kyoo-Ho Shin; Jin-Suck Suh
Journal:  J Orthop Sci       Date:  2018-02-09       Impact factor: 1.601

5.  Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Authors:  Daniel G Branstetter; Scott D Nelson; J Carlos Manivel; Jean-Yves Blay; Sant Chawla; David M Thomas; Susie Jun; Ira Jacobs
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

6.  Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.

Authors:  Kevin Marley; Shay Bracha; Bernard Seguin
Journal:  Exp Cell Res       Date:  2015-08-05       Impact factor: 3.905

7.  A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.

Authors:  Isabella W Y Mak; Nathan Evaniew; Snezana Popovic; Richard Tozer; Michelle Ghert
Journal:  J Bone Joint Surg Am       Date:  2014-08-06       Impact factor: 5.284

8.  Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.

Authors:  Hidetaka Yamamoto; Takeshi Iwasaki; Yuichi Yamada; Yoshihiro Matsumoto; Hiroshi Otsuka; Masato Yoshimoto; Kenichi Kohashi; Kenichi Taguchi; Ryohei Yokoyama; Yasuharu Nakashima; Yoshinao Oda
Journal:  Hum Pathol       Date:  2017-12-12       Impact factor: 3.466

9.  Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis.

Authors:  M Lieveld; E Bodson; G De Boeck; B Nouman; A M Cleton-Jansen; E Korsching; M S Benassi; P Picci; G Sys; B Poffyn; N A Athanasou; P C W Hogendoorn; R G Forsyth
Journal:  Virchows Arch       Date:  2014-10-11       Impact factor: 4.064

10.  Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection.

Authors:  Amit Agarwal; Brandon T Larsen; Lawrence D Buadu; Jack Dunn; Russell Crawford; Jonathan Daniel; Maria C Bishop
Journal:  Case Rep Oncol Med       Date:  2013-07-30
View more
  4 in total

Review 1.  Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.

Authors:  Aneta Maria Borkowska; Anna Szumera-Ciećkiewicz; Bartłomiej Szostakowski; Andrzej Pieńkowski; Piotr Lukasz Rutkowski
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

2.  The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone.

Authors:  Wolfram Weschenfelder; John M Abrahams; Luke J Johnson
Journal:  World J Surg Oncol       Date:  2021-02-02       Impact factor: 2.754

Review 3.  New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.

Authors:  Magdalena Woźniczka; Katarzyna Błaszczak-Świątkiewicz
Journal:  Molecules       Date:  2021-10-27       Impact factor: 4.411

4.  A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study.

Authors:  Zineb Assili; Gilles Dolivet; Julia Salleron; Claire Griffaton-Tallandier; Claire Egloff-Juras; Bérengère Phulpin
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.